TRIM33

Summary

TRIM33 (tripartite motif containing 33, HGNC:16290) is a protein-coding gene on chromosome 1p13.2, encoding E3 ubiquitin-protein ligase TRIM33 (Q9UPN9). Acts as an E3 ubiquitin-protein ligase.

The protein encoded by this gene is thought to be a transcriptional corepressor. However, molecules that interact with this protein have not yet been identified. The protein is a member of the tripartite motif family. This motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. Three alternatively spliced transcript variants for this gene have been described, however, the full-length nature of one variant has not been determined.

Source: NCBI Gene 51592 — RefSeq curated summary.

At a glance

• Gene–disease (curated): developmental dysplasia of the hip (Limited, GenCC)
• GWAS associations: 17
• Clinical variants (ClinVar): 85 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 23
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_015906

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16290
Approved symbol	TRIM33
Name	tripartite motif containing 33
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	TIF1GAMMA, FLJ11429, KIAA1113, TIFGAMMA, RFG7, TF1G, TIF1G, PTC7
Ensembl gene	ENSG00000197323
Ensembl biotype	protein_coding
OMIM	605769
Entrez	51592

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000358465, ENST00000369543, ENST00000448034, ENST00000476908, ENST00000478032, ENST00000492227, ENST00000925752, ENST00000925753, ENST00000925754, ENST00000925755, ENST00000925756, ENST00000925757, ENST00000925758, ENST00000964324, ENST00000964325

RefSeq mRNA: 2 — MANE Select: NM_015906 NM_015906, NM_033020

CCDS: CCDS872, CCDS873

Canonical transcript exons

ENST00000358465 — 20 exons

Exon	Start	End
ENSE00000784400	114427177	114427294
ENSE00000784402	114424591	114424755
ENSE00000784403	114421436	114421636
ENSE00000784404	114410184	114410316
ENSE00000784405	114408677	114408740
ENSE00000784406	114406941	114407100
ENSE00000784407	114405410	114405759
ENSE00000784408	114402760	114402883
ENSE00000784409	114401389	114401463
ENSE00000784411	114397940	114397990
ENSE00001215827	114425449	114425723
ENSE00001450301	114392790	114397860
ENSE00001595585	114463412	114463556
ENSE00001749166	114464270	114464388
ENSE00003521752	114399457	114399609
ENSE00003711583	114463104	114463236
ENSE00003720468	114433617	114433733
ENSE00003727990	114427748	114427894
ENSE00003729043	114430798	114430912
ENSE00003846759	114510551	114511203

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.8618 / max 333.5770, expressed in 1818 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13946	30.7958	1818
13944	1.0880	600
13945	0.7056	438
13940	0.1106	18
13941	0.1076	28
13942	0.0542	11

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	99.22	gold quality
secondary oocyte	CL:0000655	99.14	gold quality
oocyte	CL:0000023	98.97	gold quality
choroid plexus epithelium	UBERON:0003911	96.75	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.39	gold quality
corpus epididymis	UBERON:0004359	95.60	gold quality
nipple	UBERON:0002030	95.53	gold quality
cerebellar vermis	UBERON:0004720	95.35	gold quality
tibia	UBERON:0000979	94.68	gold quality
tongue squamous epithelium	UBERON:0006919	94.61	gold quality
CA1 field of hippocampus	UBERON:0003881	94.31	gold quality
epithelium of nasopharynx	UBERON:0001951	94.07	gold quality
seminal vesicle	UBERON:0000998	94.05	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	93.83	gold quality
gingival epithelium	UBERON:0001949	93.82	gold quality
postcentral gyrus	UBERON:0002581	93.49	gold quality
hair follicle	UBERON:0002073	93.48	gold quality
middle temporal gyrus	UBERON:0002771	93.47	gold quality
parietal lobe	UBERON:0001872	93.39	gold quality
germinal epithelium of ovary	UBERON:0001304	93.37	gold quality
visceral pleura	UBERON:0002401	93.36	gold quality
epithelial cell of pancreas	CL:0000083	93.29	gold quality
entorhinal cortex	UBERON:0002728	93.26	gold quality
caput epididymis	UBERON:0004358	93.26	gold quality
cauda epididymis	UBERON:0004360	93.19	gold quality
upper leg skin	UBERON:0004262	93.09	gold quality
cardia of stomach	UBERON:0001162	92.91	gold quality
urethra	UBERON:0000057	92.86	gold quality
corpus callosum	UBERON:0002336	92.82	gold quality
squamous epithelium	UBERON:0006914	92.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.61

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SOX2

miRNA regulators (miRDB)

389 targeting TRIM33, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713

Literature-anchored findings (GeneRIF, showing 40)

• TIF1alpha interacts with TIF1gamma and the coiled-coil region of TIF1gamma is necessary for this interaction. (PMID:12096914)
• Thus, Smad2/3-TIF1gamma and Smad2/3-Smad4 function as complementary effector arms in the control of hematopoietic cell fate by the TGFbeta/Smad pathway. (PMID:16751102)
• Study reports that TIF1gamma expression is markedly down-regulated in human pancreatic tumors by quantitative RT-PCR and immunohistochemistry. (PMID:19629168)
• Hyperthermia incurred platelet glycoprotein Ibalpha ectodomain shedding. (PMID:20158380)
• These studies are consistent with a model in which TIF1gamma acts to ubiquitinate LDB1 leading to degradation of LDB1 and changes in transcription of LDB1-dependent promoters. (PMID:20447379)
• Chromatin immunoprecipitation assays in human CD34(+) cells supported a TIF1gamma-dependent recruitment of positive elongation factors to erythroid genes to promote transcription elongation by counteracting Pol II pausing. (PMID:20603019)
• regulation of adult hematopoiesis through TIF1gamma-mediated transcriptional repression of TAL1 and PU.1 target genes. (PMID:21474105)
• TIF1gamma was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. (PMID:21537084)
• TIF1gamma binds to and represses the plasminogen activator inhibitor 1 promoter, demonstrating a direct role of TIF1gamma in TGF-beta-dependent gene expression (PMID:21597466)
• TIF1gamma dictates the residence time of activated Smad complexes at promoters of TGF-beta superfamily target genes. (PMID:21726812)
• Data suggest that over-expression of TIF1gamma occurs in early stages of colorectal carcinogenesis, is inversely related with Smad4 loss, and may be a prognostic indicator for poor outcome. (PMID:22046087)
• These results suggest that E4-ORF3 targets proteins for relocalization through a loosely homologous sequence dependent on accessibility. (PMID:22123502)
• Study reports an essential role for TRIM33 in the activation of Gsc and Mixl1 by nodal signals, and delineate how Smads gain access to poised promoters of master regulators under the command of nodal TGF-beta signals. (PMID:22196728)
• Adenovirus E4orf3 targets TIF1 gamma for proteasome-dependent degradation during infection. (PMID:22205733)
• Data suggest that the formation of transient TIF1gamma-Smad2-Smad4 ternary complexes is the only one that can account for TGF-beta signaling. (PMID:22461896)
• Tif1gamma transgene is essential for the terminal differentiation of mammary alveolar epithelial cells at the end of pregnancy and to ensure lactation. (PMID:23154409)
• TIF1gamma is an APC/C-interacting protein that regulates APC/C function. It is not a substrate for APC/C-dependent ubiquitylation but associates specifically with the APC/C holoenzyme & Cdc20 to affect APC/C activity & progression through mitosis. (PMID:23160376)
• Case Report: suggest that TIF1gamma expression in neoplasms not only determines the tumour activity but also causes dermatomyositis. (PMID:23407650)
• mutation and methylation in the promoter region of TIF1gamma in non-small cell lung cancer (PMID:23676978)
• Results identify a new TGFbeta regulatory layer, whereby sumoylation strengthens the TIF1gamma repressive action on canonical TGFbeta signaling. (PMID:23788427)
• TRIM33 plays a role in PARP-dependent DNA damage response and regulates ALC1 activity by promoting its timely removal from sites of DNA damage. (PMID:23926104)
• These studies demonstrate that anti-NXP-2 and anti-TIF-1gamma antibodies are frequent DM specificities (found in 55% of patients) and are present in most patients with cancer-associated dermatomyositis. (PMID:24037894)
• Study suggests TRIM33 and NRAS-CSDE1 as candidate genes for autism, and may provide a novel insight into the etiology of autism (PMID:24189344)
• regulates tumor growth and metastasis through inhibition of TGF-beta/Smad signaling and may serve as a novel prognostic biomarker in hepatocellular carcinoma (PMID:24954480)
• Data indicate that tripartite motif containing 33 protein TIF1gamma promotes sumoylation of SKI-like proto-oncogene protein SnoN1 and regulates epithelial-mesenchymal transition (EMT). (PMID:25059663)
• The ubiquitination of DHX33 by TRIM33 is lysine 63 specific and is required for the formation of the DHX33-NLRP3 inflammasome complex. (PMID:25172487)
• The dermatomyositis autoantigen TIF1gamma is markedly up-regulated during muscle regeneration in human and mouse muscle cells. (PMID:25186009)
• Results show that TRIM33 is significantly downregulated in clear renal cell carcinoma tissues which seems to correlate with pathologic stages and grades. (PMID:25381221)
• Tumour suppressor TRIM33 targets nuclear beta-catenin degradation (PMID:25639486)
• our findings reveal a new mechanism by which SOX2-mediated transcription repression of TIF1gamma promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancer (PMID:25961934)
• our work indicates that TIF1gamma exerts its tumor-suppressive functions in part by promoting chromosomal stability. (PMID:26282171)
• The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1gamma sumoylation and poly-SUMO chain elongation. (PMID:27247387)
• suggest that SnoN suppresses TGF-betainduced epithelial-mesenchymal transition and invasion of bladder cancer cells in a TIF1gammadependent manner (PMID:27430247)
• Data show that tripartite motif-containing protein 33 (TRIM33) silencing attenuates down-regulation of MYC and TGF-beta signaling in response to bromodomain and extraterminal domain protein inhibitors (BETi). (PMID:27432991)
• Anti-TIF1gamma antibodies are rarely present in patients with solid cancers or paraneoplastic rheumatic syndromes. This finding strengthens the approach to using anti-TIF1gamma IgG as a marker for cancer-associated dermatomyositis. (PMID:28704599)
• Tumors from paraneoplastic anti-TIF1gamma-positive cancer-associated myositis patients showed an increased number of genetic alterations, such as mutations and loss of heterozygosity, in TIF1 genes. (PMID:29149307)
• Not only did anti-TIF1gamma antibodies correlate strongly with malignancy in dermatomyositis patients, but cancers were also significantly more advanced in anti-TIF1gamma-positive DM patients than in anti-TIF1gamma-negative patients. (PMID:29745874)
• These results suggest that nuclear c-Abl-mediated tyrosine phosphorylation of TIF1gamma has a desuppressive role in TGF-beta-Smad2/3 signaling. (PMID:30177833)
• Our findings show that circPTK2 (hsa_circ_0008305) inhibits TGF-beta-induced EMT and metastasis by controlling TIF1gamma in NSCLC, revealing a novel mechanism by which circRNA regulates TGF-beta-induced EMT and tumor metastasis, and suggesting that circPTK2 overexpression could provide a therapeutic strategy for advanced NSCLC. (PMID:30261900)
• The expression of TIF1gamma in the muscle of idiopathic inflammatory myopathies was related to the positivity for serum anti-TIF1gamma antibody and presence of tubuloreticular bodies in the muscle biopsies. (PMID:30398003)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	trim33	ENSDARG00000016181
mus_musculus	Trim33	ENSMUSG00000033014
rattus_norvegicus	Trim33	ENSRNOG00000018946

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890)

Protein

Protein identifiers

E3 ubiquitin-protein ligase TRIM33 — Q9UPN9 (reviewed: Q9UPN9)

Alternative names: Ectodermin homolog, RET-fused gene 7 protein, RING-type E3 ubiquitin transferase TRIM33, Transcription intermediary factor 1-gamma, Tripartite motif-containing protein 33

All UniProt accessions (2): Q9UPN9, H0Y612

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:16751102, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/progenitor. Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade).

Subunit / interactions. Homooligomer and heterooligomer with TRIM24 and TRIM28 family members. Interacts with SMAD4 in unstimulated cells. Found in a complex with SMAD2 and SMAD3 upon addition of TGF-beta. Interacts with SMAD2 and SMAD3. Interacts with SMAD4 under basal and induced conditions and, upon TGF-beta signaling, with activated SMAD2. Forms a ternary complex with SMAD4 and SMAD2 upon TGF-beta signaling.

Subcellular location. Nucleus.

Tissue specificity. Expressed in stem cells at the bottom of the crypts of the colon (at protein level). Expressed in colon adenomas and adenocarcinomas (at protein level). Expressed in brain, lung, liver, spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas, small intestine, ovary, colon, skeletal muscle and hematopoietic progenitors.

Post-translational modifications. Sumoylated with SUMO1.

Disease relevance. A chromosomal aberration involving TRIM33 is found in papillary thyroid carcinomas (PTCs). Translocation t(1;10)(p13;q11) with RET. The translocation generates the TRIM33/RET (PTC7) oncogene. Developmental dysplasia of the hip 4 (DDH4) [MIM:621311] An autosomal recessive form of congenital dysplasia of the hip, a common skeletal anomaly in which the normal seating of the femoral head in the acetabulum is disrupted. Its severity ranges from mild instability of the femoral head with slight capsular laxity, permitting minimal lateral displacement, through moderate lateral displacement of the femoral head, without loss of contact of the head with the acetabulum, up to complete dislocation of the femoral head from the acetabulum. The disease may be caused by variants affecting the gene represented in this entry.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the TRIM/RBCC family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UPN9-1	Alpha	yes
Q9UPN9-2	Beta

RefSeq proteins (2): NP_056990, NP_148980 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000315	Znf_B-box	Domain
IPR001487	Bromodomain	Domain
IPR001841	Znf_RING	Domain
IPR001965	Znf_PHD	Domain
IPR003649	Bbox_C	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR019786	Zinc_finger_PHD-type_CS	Conserved_site
IPR019787	Znf_PHD-finger	Domain
IPR036427	Bromodomain-like_sf	Homologous_superfamily

Pfam: PF00439, PF00628, PF00643

UniProt features (109 total): modified residue 20, cross-link 19, compositionally biased region 10, sequence variant 9, region of interest 8, binding site 8, helix 7, strand 7, turn 6, zinc finger region 4, sequence conflict 4, mutagenesis site 2, chain 1, domain 1, coiled-coil region 1, site 1, splice variant 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
7ZDD	X-RAY DIFFRACTION	1.62
5MR8	X-RAY DIFFRACTION	1.74
3U5N	X-RAY DIFFRACTION	1.95
3U5O	X-RAY DIFFRACTION	2.7
3U5P	X-RAY DIFFRACTION	2.8
8BDY	X-RAY DIFFRACTION	3.05
3U5M	X-RAY DIFFRACTION	3.08
8BD8	X-RAY DIFFRACTION	3.1
8BD9	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UPN9-F1	62.49	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 964–965 (breakpoint for translocation to form trim33-ret oncogene)

Ligand- & substrate-binding residues (8): 217; 220; 241; 245; 276; 279; 299; 304

Post-translational modifications (39): 515, 515, 535, 577, 591, 591, 598, 604, 763, 769, 793, 803, 815, 862, 951, 953, 1051, 1102, 1105, 1119 …

Mutagenesis-validated functional residues (2):

Position	Phenotype
125	abolishes e3 activity but does not affect interaction with smad4; when associated with a-128.
128	abolishes e3 activity but does not affect interaction with smad4; when associated with a-125.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity
R-HSA-9754189	Germ layer formation at gastrulation

MSigDB gene sets: 357 (showing top): GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, AAGCAAT_MIR137, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, GCM_GSPT1, MAZ_Q6, BROWNE_HCMV_INFECTION_16HR_UP, MEF2_02, AP2_Q3, BILD_SRC_ONCOGENIC_SIGNATURE, GCM_BCL2L1, TCF4_Q5, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, CAGCAGG_MIR370, ONKEN_UVEAL_MELANOMA_UP, WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), protein ubiquitination (GO:0016567), regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), negative regulation of BMP signaling pathway (GO:0030514), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (9): DNA binding (GO:0003677), ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), co-SMAD binding (GO:0070410), R-SMAD binding (GO:0070412), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear lumen (GO:0031981)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1
Gastrulation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
SMAD binding	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
protein modification by small protein conjugation	1
transforming growth factor beta receptor signaling pathway	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
BMP signaling pathway	1
regulation of BMP signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
nucleic acid binding	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
nucleus	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

2400 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIM33	SMAD2	Q15796	993
TRIM33	SMAD3	P84022	953
TRIM33	MORC3	Q14149	924
TRIM33	H3C1	P02295	840
TRIM33	SMAD4	Q13485	824
TRIM33	RET	P07949	819
TRIM33	IFIH1	Q9BYX4	818
TRIM33	SAE1	Q9UBE0	806
TRIM33	RET	P07949	786
TRIM33	TRIM28	Q13263	771
TRIM33	NCOA4	Q13772	758
TRIM33	TRIM21	P19474	752
TRIM33	TRAT1	Q6PIZ9	746
TRIM33	TRIM17	Q9Y577	731
TRIM33	H3-3A	P06351	721

IntAct

163 interactions, top by confidence:

A	B	Type	Score
SMAD3	SMAD4	psi-mi:“MI:0914”(association)	0.980
RB1CC1	ATG13	psi-mi:“MI:0914”(association)	0.820
TRIM33	TRIM24	psi-mi:“MI:0914”(association)	0.790
TRIM24	TRIM33	psi-mi:“MI:0915”(physical association)	0.790
TRIM33	SMAD4	psi-mi:“MI:0914”(association)	0.750
TRIM33	SMAD4	psi-mi:“MI:0915”(physical association)	0.750
RABGGTB	YKT6	psi-mi:“MI:0914”(association)	0.740
CNOT3	CNOT1	psi-mi:“MI:0914”(association)	0.740
HSPB2	BAG3	psi-mi:“MI:0914”(association)	0.670
SMAD2	TRIM33	psi-mi:“MI:0915”(physical association)	0.660
TRIM33	SMAD2	psi-mi:“MI:0915”(physical association)	0.660
QPRT	PIK3C2A	psi-mi:“MI:0914”(association)	0.640
KPNA1	TCERG1	psi-mi:“MI:0914”(association)	0.640
JUN	NFATC1	psi-mi:“MI:0914”(association)	0.610
TRIM28	TRIM24	psi-mi:“MI:0914”(association)	0.600
TRIM28	ZNF316	psi-mi:“MI:0914”(association)	0.530
RABGGTB	PIPSL	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
NUP62	RGPD8	psi-mi:“MI:0914”(association)	0.530
ZNF764	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530

BioGRID (605): DHX33 (Affinity Capture-Western), DHX33 (Biochemical Activity), UBE2N (Reconstituted Complex), UBE2E1 (Reconstituted Complex), UBE2D3 (Reconstituted Complex), TRIM33 (Affinity Capture-Western), TRIM33 (Reconstituted Complex), TRIM33 (Affinity Capture-Western), TRIM33 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM33 (Co-fractionation)

ESM2 similar proteins: A0A1L8GR68, A2A791, B2GUN4, E1BP74, E1BZ85, F1QLG5, F7AQ22, O00472, O15164, O15550, O70546, O88974, O95789, P49140, P55265, P70365, Q14202, Q14596, Q15047, Q15788, Q4PJW2, Q5R413, Q5RC94, Q5RDJ2, Q5VZL5, Q64127, Q69Z66, Q6H8Q1, Q6KC51, Q6NXK2, Q6P3Y5, Q6PFK1, Q7Z3K3, Q8BJ34, Q8BL65, Q8BZH4, Q8CHY6, Q8IZD4, Q8TEW8, Q8VIG2

Diamond homologs: A0A0R4IXF6, A0A7U2QYM2, A2AUY4, A2BIL7, A8DZJ1, B2KF05, B2RRD7, B2RWS6, B7ZS37, D4A7T3, E9Q2Z1, F1QW93, F1R5H6, F7DRV9, G5E8P1, G5EGM3, O15164, O60885, O74350, O88379, O95696, P13709, P21675, P25440, P35177, P45481, P51123, P55201, Q03330, Q07442, Q08D75, Q09472, Q12830, Q15059, Q1LUC3, Q23590, Q32S26, Q338B9, Q4R8Y1, Q54BA2

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
TRIM33	up-regulates	SMAD3	binding
TRIM33	“up-regulates activity”	SMAD3	binding
TRIM33	“up-regulates activity”	SMAD2	binding
TRIM33	“down-regulates quantity by destabilization”	CTNNB1	binding
Ub:E2	“up-regulates activity”	TRIM33	ubiquitination
TRIM33	“down-regulates quantity by destabilization”	CTNNB1	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 185 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of definitive endoderm	5	27.2×	1e-04
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	5	14.1×	2e-03
Gastrulation	6	11.9×	9e-04
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	5	11.8×	3e-03
TP53 Regulates Transcription of DNA Repair Genes	8	11.1×	1e-04
Deactivation of the beta-catenin transactivating complex	5	8.9×	7e-03
HIV Life Cycle	6	7.4×	5e-03
TCF dependent signaling in response to WNT	7	6.3×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
SMAD protein signal transduction	5	21.2×	6e-04
positive regulation of miRNA transcription	7	11.8×	5e-04
transcription by RNA polymerase II	13	5.3×	3e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — MBL.

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	50
Likely benign	1
Benign	8

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
4075745	NM_015906.4(TRIM33):c.1636ACA[6] (p.Thr550_Gln551insThr)	Pathogenic
3063595	NM_015906.4(TRIM33):c.1650_1651insTGT (p.Thr550_Gln551insCys)	Likely pathogenic

SpliceAI

3206 predictions. Top by Δscore:

Variant	Effect	Δscore
1:114397650:A:AC	donor_gain	1.0000
1:114397651:C:CC	donor_gain	1.0000
1:114397673:T:C	donor_gain	1.0000
1:114398004:C:CT	acceptor_gain	1.0000
1:114399455:A:AC	donor_gain	1.0000
1:114399456:C:CT	donor_gain	1.0000
1:114399456:CT:C	donor_gain	1.0000
1:114399456:CTT:C	donor_gain	1.0000
1:114399458:T:TA	donor_gain	1.0000
1:114399466:CCTT:C	donor_gain	1.0000
1:114399610:C:CC	acceptor_gain	1.0000
1:114401470:C:CT	acceptor_gain	1.0000
1:114401470:C:T	acceptor_gain	1.0000
1:114401471:A:T	acceptor_gain	1.0000
1:114406357:CATA:C	acceptor_gain	1.0000
1:114406934:AGCTT:A	donor_loss	1.0000
1:114406935:GCTT:G	donor_loss	1.0000
1:114406936:CTTA:C	donor_loss	1.0000
1:114406937:TTACC:T	donor_loss	1.0000
1:114406938:TACC:T	donor_loss	1.0000
1:114406939:A:AC	donor_gain	1.0000
1:114406939:A:C	donor_loss	1.0000
1:114406940:C:CC	donor_gain	1.0000
1:114407096:CACAG:C	acceptor_gain	1.0000
1:114407098:CAG:C	acceptor_gain	1.0000
1:114407101:C:CC	acceptor_gain	1.0000
1:114407851:T:C	donor_gain	1.0000
1:114408673:TCA:T	donor_loss	1.0000
1:114408674:CA:C	donor_loss	1.0000
1:114408675:A:AC	donor_gain	1.0000

AlphaMissense

7431 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:114397802:A:G	L1077P	1.000
1:114397814:A:G	F1073S	1.000
1:114397835:C:T	G1066E	1.000
1:114397836:C:A	G1066W	1.000
1:114397836:C:G	G1066R	1.000
1:114397836:C:T	G1066R	1.000
1:114399463:A:C	F1038L	1.000
1:114399463:A:T	F1038L	1.000
1:114399464:A:G	F1038S	1.000
1:114399465:A:G	F1038L	1.000
1:114399472:A:C	C1035W	1.000
1:114399473:C:T	C1035Y	1.000
1:114399474:A:G	C1035R	1.000
1:114399475:G:C	N1034K	1.000
1:114399475:G:T	N1034K	1.000
1:114399482:A:G	F1032S	1.000
1:114399491:C:G	R1029P	1.000
1:114399494:A:T	V1028D	1.000
1:114399506:A:G	F1024S	1.000
1:114399525:A:C	Y1018D	1.000
1:114399548:A:G	L1010P	1.000
1:114399548:A:T	L1010H	1.000
1:114399556:T:A	K1007N	1.000
1:114399556:T:G	K1007N	1.000
1:114399560:A:T	V1006E	1.000
1:114399569:A:G	L1003S	1.000
1:114399587:A:T	I997K	1.000
1:114399599:T:C	Y993C	1.000
1:114399600:A:C	Y993D	1.000
1:114399600:A:G	Y993H	1.000

dbSNP variants (sampled 300 via entrez): RS1000046024 (1:114415133 T>C), RS1000050646 (1:114430439 C>T), RS1000051280 (1:114494148 G>C), RS1000081587 (1:114470053 G>T), RS1000103253 (1:114508137 A>G), RS1000103788 (1:114407839 G>C,T), RS1000112604 (1:114443737 A>G), RS1000124950 (1:114501284 A>G), RS1000238605 (1:114400676 C>G,T), RS1000280324 (1:114393439 G>T), RS1000317939 (1:114474968 G>C), RS1000351648 (1:114456538 C>T), RS1000376420 (1:114438391 A>C,T), RS1000398886 (1:114501054 G>A), RS1000417346 (1:114393957 G>C,T)

Disease associations

OMIM: gene MIM:605769 | disease phenotypes: MIM:167000, MIM:142700, MIM:621311

GenCC curated gene-disease

Disease	Classification	Inheritance
developmental dysplasia of the hip	Limited	Autosomal recessive

Mondo (3): ovarian cancer (MONDO:0008170), developmental dysplasia of the hip (MONDO:0000158), developmental dysplasia of the hip 4 (MONDO:0979872)

Orphanet (1): Rare ovarian cancer (Orphanet:213500)

HPO phenotypes

23 total (23 of 23 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000023	Inguinal hernia
HP:0000079	Abnormality of the urinary system
HP:0000160	Narrow mouth
HP:0000174	Abnormal palate morphology
HP:0000272	Malar flattening
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000364	Hearing abnormality
HP:0000431	Wide nasal bridge
HP:0000457	Depressed nasal ridge
HP:0000463	Anteverted nares
HP:0001374	Congenital hip dislocation
HP:0001382	Joint hypermobility
HP:0001385	Hip dysplasia
HP:0001643	Patent ductus arteriosus
HP:0001671	Abnormal cardiac septum morphology
HP:0001702	Abnormal tricuspid valve morphology
HP:0002815	Abnormality of the knee
HP:0003577	Congenital onset
HP:0004097	Deviation of finger
HP:0010759	Prominence of the premaxilla
HP:0011328	Abnormal fontanelle morphology

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST002268_3	Autism	2.000000e-07
GCST002268_4	Autism	6.000000e-08
GCST002268_5	Autism	6.000000e-08
GCST002268_6	Autism	4.000000e-08
GCST002268_7	Autism	8.000000e-08
GCST002268_8	Autism	7.000000e-08
GCST002268_9	Autism	3.000000e-08
GCST004630_9	Mean corpuscular hemoglobin	3.000000e-14
GCST007576_116	Chronotype	8.000000e-09
GCST010151_3	Carotid intima media thickness x smoking interaction	9.000000e-06
GCST90002390_9	Mean corpuscular hemoglobin	1.000000e-20
GCST90002392_276	Mean corpuscular volume	7.000000e-23
GCST90002396_140	Mean reticulocyte volume	4.000000e-20
GCST90002397_770	Mean spheric corpuscular volume	6.000000e-20
GCST90002401_353	Platelet distribution width	1.000000e-10
GCST90002403_14	Red blood cell count	1.000000e-09
GCST90002404_472	Red cell distribution width	2.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0008328	chronotype measurement
EFO:0006527	smoking status measurement
EFO:0010701	mean reticulocyte volume
EFO:0007984	platelet component distribution width
EFO:0004305	erythrocyte count
EFO:0009188	Red cell distribution width

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D000082602	Developmental Dysplasia of the Hip	C05.550.518.384.500; C05.660.297; C16.131.621.297
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2176772 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TIF1 family

ChEMBL bioactivities

40 potent at pChembl≥5 of 96 total, top 40 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.50	IC50	3.19	nM	CHEMBL4440737
7.86	IC50	13.72	nM	CHEMBL4470967
6.85	IC50	140	nM	MOLIBRESIB
6.76	Kd	173	nM	MOLIBRESIB
6.63	IC50	233.5	nM	CYCLOPENTANONE
6.62	IC50	240.3	nM	CHEMBL4467793
6.60	IC50	249.8	nM	CYCLOOCTANONE
6.57	IC50	268.9	nM	CHEMBL4572394
6.55	IC50	283.4	nM	CHEMBL543846
6.52	IC50	299.4	nM	SALICYLADEHYDE
6.52	IC50	300.6	nM	CHEMBL350966
6.51	IC50	305.4	nM	CHEMBL2229659
6.50	IC50	319.8	nM	CHEMBL4451080
6.49	IC50	325.6	nM	VANILLIN
6.47	IC50	335.7	nM	CHEMBL4592980
6.27	IC50	537.9	nM	CHEMBL4448530
6.26	IC50	553.2	nM	CHEMBL4452179
6.19	IC50	641	nM	CHEMBL4446283
5.99	IC50	1026	nM	CHEMBL4452792
5.97	IC50	1069	nM	CHEMBL4449227
5.93	IC50	1165	nM	CHEMBL4446283
5.89	IC50	1294	nM	CHEMBL4580867
5.87	IC50	1356	nM	CHEMBL4457083
5.87	IC50	1365	nM	CHEMBL4438332
5.71	IC50	1934	nM	CHEMBL4470369
5.46	IC50	3457	nM	CHEMBL4453026
5.45	IC50	3576	nM	CHEMBL4461534
5.44	IC50	3597	nM	CHEMBL4461549
5.42	IC50	3777	nM	CHEMBL4461534
5.33	IC50	4690	nM	CHEMBL4303781
5.26	IC50	5484	nM	CHEMBL4473237
5.23	IC50	5901	nM	CHEMBL4465785
5.20	IC50	6323	nM	CHEMBL3774575
5.14	IC50	7172	nM	CHEMBL4586564
5.13	IC50	7451	nM	CHEMBL4548728
5.10	IC50	7884	nM	CHEMBL4470427
5.07	IC50	8574	nM	CHEMBL4546478
5.06	IC50	8718	nM	CHEMBL4445295
5.02	IC50	9597	nM	CHEMBL4457958
5.00	IC50	1.007e+04	nM	CHEMBL4560434

PubChem BioAssay actives

2 with measured affinity, of 46 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178558: Inhibition of TRIM33 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.1400	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	6
bisphenol A	decreases expression, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
2,4,6-tribromophenol	decreases expression	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	increases expression	1
cobaltous chloride	increases expression	1
nickel sulfate	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
tamibarotene	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	decreases expression	1
(+)-JQ1 compound	decreases expression, decreases reaction, increases expression, affects binding, increases reaction (+2 more)	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Caffeine	affects phosphorylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1

ChEMBL screening assays

47 unique, capped per target: 47 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2186997	Binding	Inhibition of His6FLAG-tagged TRIM33 isoform B expressed in Escherichia coli assessed as change in melting temperature at 100 uM by thermal shift assay	Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8RE	Abcam HCT 116 TRIM33 KO	Cancer cell line	Male
CVCL_B9TT	Abcam A-549 TRIM33 KO	Cancer cell line	Male
CVCL_TU09	HAP1 TRIM33 (-) 1	Cancer cell line	Male
CVCL_TU10	HAP1 TRIM33 (-) 2	Cancer cell line	Male
CVCL_TU11	HAP1 TRIM33 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

384 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00208364	PHASE4	TERMINATED	A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement
NCT00208377	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00208390	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement
NCT00208429	PHASE4	WITHDRAWN	A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement
NCT00208442	PHASE4	COMPLETED	A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement
NCT00208455	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
NCT00546598	PHASE4	TERMINATED	Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System
NCT00715026	PHASE4	TERMINATED	Trilogy AB Acetabular Hip System Post Approval Study
NCT00872066	PHASE4	COMPLETED	A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement
NCT00872222	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement
NCT00872547	PHASE4	TERMINATED	Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
NCT00872573	PHASE4	TERMINATED	A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement
NCT00872794	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00873444	PHASE4	TERMINATED	A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing
NCT01134445	PHASE4	TERMINATED	An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
NCT01422564	PHASE4	TERMINATED	Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem
NCT01635166	PHASE4	TERMINATED	Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib